Convergent R.N.R.

Convergent Radiotherapy and Radiosurgery is a medical start-up developing a new X-ray-focusing technology called MercyBeam. The companys patented technology uses a standard imaging X-ray source to form a converging beam into a volume of treatment, rather than the standard diverging one. This development is designed to render radiotherapy treatment more accurate and safe and to spare healthy organs and cells. MercyBeam introduces a lens that collects most of the X-rays emanating divergently out of any standard X-ray tube and converges themtoward the tumors location. The lens simultaneously removes low-energy photons that would be absorbed by the patients skin. The convergence increases the therapeutic dose delivered at the tumor location, while the organs in the vicinity of the tumor receive a very low dose or none at all. The converging technology enables the use of photon-energy X-rays 100 times lower than those used by current systems based on linear accelerators.

Convergent R.N.R. has raised $3.7M in total funding across 2 rounds. The company is currently at the Mature stage. Key investors include Office of the Chief Scientist.

Convergent R.N.R. was founded in 2010 by Ze'ev Harel (Co-founder & CEO), Dr. Aharon Bar-David (Co-Founder & Chief physicist), Avigail Keller (Co-founder), Zeev Burshtein (Co-founder).

Convergent R.N.R. operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Simulation & Imaging. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers.

Convergent R.N.R. is based in Andrei Sakharov St 9, Haifa, Israel, North District.